Year

2017
Lead candidate, light-activated AU-011, currently being investigated in Phase 1b/2 study to treat ocular melanoma, an orphan indication Funding to support ongoing clinical development, enabling buildout of company infrastructure and GMP manufacturing CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle...
Last Patient Last Visit (LPLV) completed in Phase II Study for the Treatment of Calcific Uraemic Arteriolopathy in End Stage Renal Disease Patients Palma, Spain and San Diego, USA, December 21, 2017 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, announced today that the Last Patient’s Last Visit (LPLV) occurred...
Approval granted several months ahead of the initial schedule Launch of HEMOBLAST™ Bellows in the United States expected over the summer in 2018 Saint-Priest, France, December 18, 2017 – Biom’Up, specialist in surgical hemostasis, announces today that it has received FDA marketing approval for HEMOBLASTTM Bellows, its flagship product, 7 months ahead of schedule. This pre-marketing...
Lund, Sweden, 08.00 CET, 13 December 2017 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces that it has achieved its aim of recruiting 136 patients into the CERTiFy (CERAMENT® Treatment of Fracture defects)...
BURLINGTON, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to transform infused therapies, advance patient care and reduce healthcare costs, today announced that Troy A. Ignelzi, chief financial officer of scPharmaceuticals, will present at the BMO Capital Markets Prescriptions for Success Healthcare Conference at 4:30 PM ET on Thursday, December...
December 12, 2017 –OXFORD, UK – PsiOxus Therapeutics, Ltd. (PsiOxus) today announced that the Clinical Trial Application for NG-348, an “armed” oncolytic virus for the treatment of solid tumors, has been approved and, per the licensing agreement between the parties, Bristol-Myers Squibb will make a US $15 million milestone payment to PsiOxus. “This is an exciting development...
Med opslaget af to store tematiske programmer indenfor hjernesygdomme er Lundbeckfonden klar til at støtte ny dansk hjerneforskning med op til 250 mio. kr. i 2018. Det største opslag fokuserer på personlig medicin og bakker dermed op om den nationale strategi på området. Hjernesygdomme koster samfundet mere end kræft, diabetes og hjerte-kar-sygdomme tilsammen. Alligevel ved...
Et dansk-amerikansk forskningsprojekt har ved hjælp af en snedig beregningsmetode identificeret yderligere 62 humane gener, som med ”en meget høj grad af sandsynlighed” kan udvikle kræftfremkaldende mutationer. Metoden gør det muligt at finde årsagen til mange tilfælde af kræft, som i dag må rubriceres som ’uforklarlige’. Man kan få svar på en hel del spørgsmål...
”Vi sætter hjernen først”. Sådan lyder overskriften på den nye strategi for Lundbeckfondens almennyttige aktiviteter. Et af målene i strategien er, at Danmark skal være blandt de førende hjerneforskningsnationer i verden, og på den baggrund vil fonden over de kommende år øge sine uddelinger til det neurovidenskabelige område betragteligt. For at gøre det på et...
Lund, Sweden, 18:00 CET 30 November 2017 – During November, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 30 November 2017, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 50,000,821. For more information contact: Richard Davies, CEO...
1 2 3 14

Nyheder

Lundbeckfonden vil dække universiteters projektrelaterede indirekte omkostninger
10. december 2018
Danske forskere: Patientforsøg med stamceller mod diabetes nærmer sig
10. december 2018
Professor søges!
5. december 2018

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge